1. Home
  2. SLND vs ARTV Comparison

SLND vs ARTV Comparison

Compare SLND & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLND
  • ARTV
  • Stock Information
  • Founded
  • SLND 1900
  • ARTV 2019
  • Country
  • SLND United States
  • ARTV United States
  • Employees
  • SLND N/A
  • ARTV N/A
  • Industry
  • SLND Military/Government/Technical
  • ARTV
  • Sector
  • SLND Industrials
  • ARTV
  • Exchange
  • SLND Nasdaq
  • ARTV NYSE
  • Market Cap
  • SLND 175.8M
  • ARTV 186.1M
  • IPO Year
  • SLND N/A
  • ARTV 2024
  • Fundamental
  • Price
  • SLND $2.98
  • ARTV $3.00
  • Analyst Decision
  • SLND Strong Buy
  • ARTV Strong Buy
  • Analyst Count
  • SLND 1
  • ARTV 7
  • Target Price
  • SLND $5.00
  • ARTV $20.00
  • AVG Volume (30 Days)
  • SLND 58.7K
  • ARTV 133.1K
  • Earning Date
  • SLND 03-04-2025
  • ARTV 05-22-2025
  • Dividend Yield
  • SLND N/A
  • ARTV N/A
  • EPS Growth
  • SLND N/A
  • ARTV N/A
  • EPS
  • SLND N/A
  • ARTV N/A
  • Revenue
  • SLND $980,179,000.00
  • ARTV $251,000.00
  • Revenue This Year
  • SLND $4.06
  • ARTV N/A
  • Revenue Next Year
  • SLND $7.16
  • ARTV N/A
  • P/E Ratio
  • SLND N/A
  • ARTV N/A
  • Revenue Growth
  • SLND N/A
  • ARTV N/A
  • 52 Week Low
  • SLND $1.85
  • ARTV $2.92
  • 52 Week High
  • SLND $5.98
  • ARTV $17.31
  • Technical
  • Relative Strength Index (RSI)
  • SLND 38.56
  • ARTV N/A
  • Support Level
  • SLND $3.15
  • ARTV N/A
  • Resistance Level
  • SLND $3.23
  • ARTV N/A
  • Average True Range (ATR)
  • SLND 0.12
  • ARTV 0.00
  • MACD
  • SLND -0.04
  • ARTV 0.00
  • Stochastic Oscillator
  • SLND 2.00
  • ARTV 0.00

About SLND Southland Holdings Inc.

Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.

About ARTV ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.

Share on Social Networks: